Physician profile
David S Darr
NPI 1447293402
$8,601.03
in general payments reported to CMS, 2019-2025
59 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $764 · 2021: $1,046 · 2022: $1,327 · 2023: $1,299 · 2024: $2,022 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,666.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.71 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $752.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $591.60 | 2019-2025 | |
| Lilly USA, LLC | $477.92 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.65 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $433.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Inspire Medical Systems, INC. | $254.92 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $237.74 | 2023-2025 | Sunosi, Auvelity |
| Amgen INC. | $225.16 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.32 | 2019-2025 | Jardiance |
| Shield Therapeutics INC | $217.11 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $204.87 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $176.60 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $176.40 | 2020-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $147.92 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Darr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.